GPRC5D-Directed Therapies Market Analysis 2025: Emerging Treatment 

The GPRC5D-directed Therapies market across the 7MM is anticipated to expand at a substantial CAGR by 2034 in major countries (US, EU4, UK and Japan).

Discover comprehensive insights into the GPRC5D-directed Therapies market landscape @ GPRC5D-Directed Therapies Market Report

Key Takeaways from the GPRC5D-Directed Therapies Market Report

• The GPRC5D-directed Therapies Market Size is expected to expand with a significant CAGR throughout the study period (2020-2034).

• G protein-coupled receptor, class C group 5 member D (GPRC5D), positioned on human chromosome 12p13, is an orphan G-protein coupled receptor. GPRC5D protein is predominantly expressed in cells with a plasma cell phenotype and has minimal to no expression in normal B cells, T cells, natural killer cells, monocytes, granulocytes, and bone marrow progenitors.

• GPRC5D exhibits high expression in multiple myeloma cells and is abundant in the bone marrow of individuals with multiple myeloma and smoldering multiple myeloma.

• Presently, TALVEY (talquetamab-tgvs), approved in August 2023, represents the first and the only approved GPRC5D-directed therapy available in the market.

• Several major emerging key GPRC5D-directed Therapies Companies in the market include CARsgen Therapeutics (CT071), Oricell (OriCAR-017), Bristol-Myers Squibb (Arlocabtagene autoleucel), AstraZeneca (AZD0305), Sanofi, Oncostellae, among additional organizations.

• According to DelveInsight's estimates, the total market size in the US for multiple myeloma reached approximately ~USD 15,000 million in 2024, which is anticipated to demonstrate positive growth.

• In June 2025, CARsgen Therapeutics presented a Phase I investigation of CT071 for managing newly diagnosed multiple myeloma at the European Hematology Association (EHA) website.

• Oricell Therapeutics presented the two-year long-term follow-up results of OriCAR-017, an open-label Phase I investigation evaluating GPRC5D-targeted CAR-T therapy in individuals with relapsed/refractory multiple myeloma, in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Want to know which GPRC5D-directed Therapies Companies are leading innovation? Explore comprehensive market intelligence @ GPRC5D-Directed Therapies Clinical Trials

GPRC5D-Directed Therapies Market and Epidemiology Analysis

In the crowded multiple myeloma market with several approved and emerging CAR-Ts, GPRC5D-directed Therapies CAR-T therapies represent an innovative approach to multiple myeloma management.

According to DelveInsight's analysis, the growth of the GPRC5D-directed Therapies market is anticipated to be primarily driven by the expected launch of various emerging therapies, including CT071, OriCAR-017, BMS-986393, AZD0305, SIM0500, among others.

GPRC5D-Directed Therapies Market Forecast

DelveInsight's "GPRC5D-directed Therapies Market Size, Target Population, Competitive Landscape, and Market Forecast – 2034" report delivers comprehensive intelligence into GPRC5D-directed Therapies, historical and competitive landscape as well as therapeutic market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The GPRC5D-directed Therapies market report provides current treatment practices, emerging GPRC5D-directed Therapies Drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034 across 7MM. The report also covers currently approved therapies and unmet medical requirements to identify optimal opportunities and assess market potential.

Study Period: 2020 to 2034

Forecast Period: 2024-2034

Geographies Covered: The US, EU4 (Germany, France, Italy, and Spain) and UK, Japan

Access detailed market forecasts and competitive analysis @ GPRC5D-Directed Therapies Market Forecast 

GPRC5D-Directed Therapies Market Insights

• Total Market Size

• Market Size by Therapies

• Market Size by Class

GPRC5D-directed Therapies Market Size: USD XX Million by 2034

GPRC5D-directed Therapies Companies: Bristol-Myers Squibb, AstraZeneca, Oricell, CARsgen Therapeutics, Sanofi, Oncostellae, among others

GPRC5D-Directed Therapies Patient Pool Segmentation

• Total Cases in Selected Indications for GPRC5D-directed Therapies

• Total Eligible Patient Pool in Selected Indications for GPRC5D-directed Therapies

• Total Treated Cases in Selected Indications for GPRC5D-directed Therapies

GPRC5D-Directed Therapies Overview

GPRC5D, positioned on human chromosome 12p13, is an orphan G-protein coupled receptor, meaning its ligand remains unknown. GPRC5D is a validated target for multiple myeloma therapeutics. In early Phase trials, GPRC5D-targeting T-cell–redirecting agents have demonstrated promising efficacy and manageable safety profiles, requiring confirmation in Phase III trials.

GPRC5D exhibits high expression in multiple myeloma cells and is abundant in the bone marrow of individuals with multiple myeloma and smoldering multiple myeloma. Additionally, GPRC5D mRNA expression is elevated in multiple myeloma cells compared to other hematologic cancers. The selective expression in multiple myeloma cells suggests that GPRC5D represents an ideal target for immune effector cell-mediated therapy to manage multiple myeloma.

GPRC5D-targeting T-cell–redirecting therapies, as monotherapy or combined with other anti-myeloma agents, will expand treatment options available for individuals with multiple myeloma. These therapies may provide options for individuals requiring treatment with a novel mechanism of action that preserves BCMA-targeting therapy for subsequent treatment lines, have experienced suboptimal response or antigen loss with other agents, or for individuals exhibiting clonal heterogeneity.

While GPRC5D and BCMA demonstrate similar expression on CD138+ cells, the expression patterns are independent of each other, offering distinct clinical targets. GPRC5D expression remains unaffected by BCMA loss, which has been associated with disease relapse following treatment with BCMA-targeting therapies and may support combining GPRC5D-targeting and BCMA-targeting T-cell redirecting agents to address multiple myeloma heterogeneity.

Learn more about GPRC5D-directed Therapies patient demographics and epidemiology @ GPRC5D-Directed Therapies Epidemiology

GPRC5D-Directed Therapies Patient Pool

The GPRC5D-directed Therapies epidemiology chapter provides historical and forecasted epidemiology segmented as total cases in selected indications (multiple myeloma), total eligible patient pool, and total treated cases in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.

• In the US, there were approximately 33,700 incident cases of multiple myeloma in 2024, representing the highest among seven major markets.

• Multiple myeloma is more prevalent in males compared to females. In the United States, approximately 56% of males were diagnosed with multiple myeloma in 2024.

• Regarding age-specific cases of multiple myeloma, the age group of 65 and above years has the highest number of cases, followed by 55–64 and 0–54 years.

• In Japan, there were nearly 5,400 first-line transplant ineligible cases and nearly 1,300 first-line transplant eligible cases in 2024.

If you're tracking ongoing GPRC5D-directed Therapies Clinical Trials, this report is essential. Access breakthrough insights @ GPRC5D-Directed Therapies Clinical Development

GPRC5D-Directed Therapies Drug Profiles

The drug chapter segment encloses comprehensive analysis of GPRC5D-directed Therapies targeting pipeline medications in different phases of development. It also helps understand GPRC5D-directed Therapies Clinical Trials details, pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and latest updates.

Marketed GPRC5D-Directed Therapies

TALVEY (talquetamab-tgvs): Johnson & Johnson Innovative Medicine (Janssen Biotech)

TALVEY is a first-in-class bispecific T-cell engaging antibody that binds to the CD3 receptor on T cell surfaces and G protein-coupled receptor class C group 5 member D (GPRC5D) expressed on multiple myeloma cell surfaces, non-malignant plasma cells and healthy tissue including epithelial cells in keratinized tissues of the skin and tongue. TALVEY is approved as a weekly or biweekly subcutaneous (SC) injection following an initial step-up phase, offering physicians flexibility to determine optimal treatment regimens for individuals.

Emerging GPRC5D-Directed Therapies Drugs

OriCAR-017: Oricell

OriCAR-017, a Chimeric Antigen Receptor (CAR) T cell therapy targeting GPRC5D, represents a groundbreaking innovation for managing relapsed/refractory multiple myeloma. Leveraging Oricell Therapeutics' cutting-edge proprietary technology platforms, OriCAR-017 exhibits differentiated binding avidity, persistence, anti-tumor efficacy, and safety profile. OriCAR-017 received IND approval from the FDA in January 2024 following its approval by NMPA in 2023.

Arlocabtagene autoleucel (BMS-986393): Bristol Myers Squibb (Juno Therapeutics)

BMS-986393 is a GPRC5D-directed autologous CAR T cell therapy. The company is currently conducting a Phase II (QUINTESSENTIAL) trial in relapsed/refractory multiple myeloma with projected data readout in 2026. At the ASH 2023 conference, updated data from the Phase I investigation of BMS-986393 showed deepening responses, a tolerable safety profile, and activity across both B-cell maturation antigen (BCMA)-naïve and -exposed individuals.

CT071: CARsgen Therapeutics

CT071 is an autologous CAR T cell therapy being developed by CARsgen Therapeutics for managing multiple myeloma. The therapy is currently undergoing Phase I/II GPRC5D-directed Therapies Clinical Trials evaluation with promising preliminary results presented at major oncology conferences.

GPRC5D-Directed Therapies Market Outlook

GPRC5D has emerged as a promising therapeutic target for managing multiple myeloma. Preclinical investigations have demonstrated the efficacy of GPRC5D-directed Therapies CAR-T cells using a human-derived GPRC5D-targeted scFv clone 109 (GPRC5D[109]) in various multiple myeloma cell lines, including primary cells from bone marrow aspirates.

Ongoing trials are exploring the safety and effectiveness of combining these T-cell–redirecting agents with other anti-myeloma treatments for individuals with relapsed or refractory multiple myeloma. These combinations include talquetamab with teclistamab, daratumumab, pomalidomide, anti-PD-1 antibodies, carfilzomib, and lenalidomide. This suggests that GPRC5D-targeting bispecific antibodies could be versatile partners in combination therapies.

However, managing GPRC5D-associated adverse events requires further investigation into dose modification strategies, such as reduced frequency or fixed-duration dosing, and other mitigation measures. These approaches aim to balance the potential toxicity related to on-target effects with the promising efficacy seen in these therapies.

In addition to CAR-T therapies, ongoing research includes CAR–natural killer cell therapies, bispecific–natural killer cell engagers, and antibody-drug conjugates, which collectively offer potential advancements in treating multiple myeloma.

Key GPRC5D-directed Therapies Companies in the market include CARsgen Therapeutics, Oricell, Bristol-Myers Squibb, AstraZeneca, Sanofi, among others.

Stay informed about market dynamics and competitive landscape @ GPRC5D-Directed Therapies Market Drivers and Barriers 

Key Updates on GPRC5D-Directed Therapies

• According to Bristol-Myers Squibb's first quarter presentation, the company anticipates the New Molecular Entity (NME) registrational data of Arlo-cel for the RRMM QUINTESSENTIAL study in 2026.

• In January 2025, AbbVie and Simcere Zaiming announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently in Phase I GPRC5D-directed Therapies Clinical Trials in individuals with relapsed or refractory multiple myeloma (MM), in both China and the US.

• As per the first quarter presentation of Bristol-Myers Squibb, the GPRC5D-directed Therapies Companies anticipate significant data readouts that will shape future treatment paradigms.

KOL Views on GPRC5D-Directed Therapies

DelveInsight's analysts connected with 25+ KOLs to gather insights; interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Multiple Myeloma Research Foundation, Dana-Farber Cancer Institute, University of Texas MD Anderson Cancer Center were contacted.

KOL Insights:

"Results from the MonumenTAL-1 study continue to show deeper response levels and a longer duration of response in patients treated with either of the approved dose options of talquetamab, while the median overall survival has yet to be reached at two years."

"Arlo-cel, a potential first-in-class, GPRCD-targeted, autologous CAR T-cell therapy administered to patients with heavily pretreated relapsed/refractory multiple myeloma, showed manageable safety and promising efficacy."

Access expert KOL perspectives and market insights @ GPRC5D-Directed Therapies Expert Analysis

Scope of the GPRC5D-Directed Therapies Market Report

The report covers key events, executive summary, and descriptive overview of multiple myeloma, explaining its causes, diagnosis, and therapies (current and emerging).

Comprehensive insight into the competitive landscape, forecasts, future growth potential of treatment rate, drug uptake, and GPRC5D-directed Therapies Drugs information have been provided.

Additionally, an all-inclusive account of current and emerging therapies and elaborative profiles of late-stage and prominent therapies will impact the current landscape.

A detailed review of the GPRC5D-directed Therapies market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.

The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis, expert insights/KOL views, and treatment preferences that shape and drive the 7MM GPRC5D-directed Therapies market.

GPRC5D-Directed Therapies Market Report Insights

• GPRC5D-directed Therapies Patient Pool

• GPRC5D-directed Therapies Therapeutic Approaches

• GPRC5D-directed Therapies Pipeline Analysis

• GPRC5D-directed Therapies Market Size and Trends

• Existing and Future Market Opportunity

Download sample report to understand market dynamics @ GPRC5D-Directed Therapies Market Sample 

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of GPRC5D-directed therapies

4. Key Events

5. Market Forecast Methodology

6. GPRC5D-directed therapies Market Overview at a Glance in the 7MM

6.1. Market Share (%) Distribution by Therapies in 2023

6.2. Market Share (%) Distribution by Therapies in 2034

7. GPRC5D-directed therapies: Background and Overview

7.1. Introduction

7.2. Treatment

8. Target Patient Pool

8.1. Key Findings

8.2. Assumptions and Rationale: 7MM

8.3. Epidemiology Scenario in the 7MM

8.4. Total Cases in Selected Indications for GPRC5D-directed therapies in the 7MM

8.5. Total Eligible Patient Pool for GPRC5D-directed therapies in Selected Indications in the 7MM

8.6. Total Treated Cases in Selected Indications for GPRC5D-directed therapies in the 7MM

9. Marketed Therapies

9.1. TALVEY (talquetamab-tgvs): Johnson & Johnson Innovative Medicine

9.1.1. Product Description

9.1.2. Regulatory Milestones

9.1.3. Other Developmental Activities

9.1.4. Clinical Development

9.1.5. Safety and Efficacy

9.1.6. Analyst Views

10. Emerging Therapies

10.1. Key Competitors

10.2. OriCAR-017: Oricell

10.2.1. Product Description

10.2.2. Other Developmental Activities

10.2.3. Clinical Development

10.2.4. Safety and Efficacy

10.2.5. Analyst Views

10.3. Arlocabtagene autoleucel (BMS-986393): Bristol Myers Squibb (Juno Therapeutics)

10.3.1. Product Description

10.3.2. Other Developmental Activities

10.3.3. Clinical Development

10.3.4. Safety and Efficacy

10.3.5. Analyst Views

List to be continued in the report

11. GPRC5D-directed Therapies: Seven Major Market Analysis

11.1. Key Findings

11.2. Market Outlook

11.3. Conjoint Analysis

11.4. Key Market Forecast Assumptions

11.4.1. Cost Assumptions and Rebates

11.4.2. Pricing Trends

11.4.3. Analogue Assessment

11.4.4. Launch Year and Therapy Uptakes

11.5. Total Market Size of GPRC5D-directed therapies in the 7MM

11.6. Market Size of GPRC5D-directed therapies by Indication in the7MM

11.7. Market Size of GPRC5D-directed therapies by Therapies in the 7MM

11.8. The United States Market Size

11.8.1. Market Size of GPRC5D-directed therapies by Indication in the United States

11.8.2. Market Size of GPRC5D-directed therapies by Therapies in the United States

11.9. EU4 and the UK Market Size

11.9.1. Market Size of GPRC5D-directed therapies by Indication in EU4 and the UK

11.9.2. Market Size of GPRC5D-directed therapies by Therapies in EU4 and the UK

11.10. Japan Market Size

11.10.1. Market Size of GPRC5D-directed therapies by Indication in Japan

11.10.2. Market Size of GPRC5D-directed therapies by Therapies in Japan

12. Market Access and Reimbursement

13. SWOT Analysis

14. KOL Views

15. Unmet Needs

16. Appendix

About DelveInsight

DelveInsight is a premier healthcare-oriented market research and advisory organization that delivers clients superior market intelligence and analysis to facilitate informed business strategies. Supported by a team of seasoned industry specialists and comprehensive knowledge of the life sciences and healthcare industries, we provide tailored research solutions and strategic insights to clients worldwide.

Contact Us

Kanishk

kkumar@delveinsight.com